SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function

Lonsdale, DO; Lipman, J; Livermore, A; McWhinney, B; Ungerer, JPJ; Roberts, JA (2020) Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. Chemotherapy, 64 (4). pp. 173-176. ISSN 0009-3157 https://doi.org/10.1159/000505057
SGUL Authors: Lonsdale, Dagan

[img] Microsoft Word (.docx) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (49kB)
[img] Microsoft Word (.docx) Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (15kB)

Abstract

Dosing of amoxicillin-clavulanic acid in critical illness is difficult as β-lactam pharmacokinetics are altered by physiological changes and therapies initiated in the intensive care unit such as renal replacement therapy (RRT). Successful treatment relies on sustaining a free antibiotic concentration above the minimum inhibitory concentration of the target pathogen (fT>MIC). We present a case of a patient treated with amoxicillin-clavulanic acid (1.2 g for 8 h) for an aspiration pneumonia. Dosing in this case was complicated by the necessity for RRT to treat a drug overdose with carbamazepine, despite normal native renal function. Antibiotic concentrations taken at steady state revealed a clearance of 14.6 L/h and a low fT>MIC (<40%). Analysis of the urine drug concentration suggested that 48% of clearance was via the native kidneys. This case illustrates that careful consideration of antibiotic dose and frequency is required in critically ill patients receiving RRT and highlights the need for further research in this patient group. In future similar cases, we would consider a dose of 2.2 g 6- or 8-hourly with early therapeutic drug monitoring.

Item Type: Article
Additional Information: This is the peer-reviewed but unedited manuscript version of the following article: Chemotherapy 2019;64:173–176. The final, published version is available at http://www.karger.com/?doi=10.1159/000505057
Keywords: 1115 Pharmacology and Pharmaceutical Sciences, Microbiology
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Biomedical Education (INMEBE)
Journal or Publication Title: Chemotherapy
ISSN: 0009-3157
Language: en
Dates:
DateEvent
March 2020Published
15 January 2020Published Online
27 November 2019Accepted
Publisher License: Publisher's own licence
URI: https://openaccess.sgul.ac.uk/id/eprint/112072
Publisher's version: https://doi.org/10.1159/000505057

Actions (login required)

Edit Item Edit Item